key: cord-0288316-50q3wa6y
authors: Thi My, Vo Hoa; Alvino, Maestri; Heidi, Auerswald; Sopheak, Sorn; Sokchea, Lay; Seng, Heng; Sotheary, Sann; Nisa, Ya; Polidy, Pean; Philippe, Dussart; Olivier, Schwartz; Sovann, Ly; Timothee, Bruel; Sowath, Ly; Veasna, Duong; Erik A, Karlsson; Tineke, Cantaert
title: Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort
date: 2021-08-12
journal: bioRxiv
DOI: 10.1101/2021.08.12.455901
sha: 806f7dce97d948e9e78dabda899c25aad930ac79
doc_id: 288316
cord_uid: 50q3wa6y

Assessing the duration of humoral and cellular immunity remains key to overcome the current SARS-CoV-2 pandemic, especially in understudied populations in least developed countries. Sixty-four Cambodian individuals with laboratory-confirmed infection with asymptomatic or mild/moderate clinical presentation were evaluated for humoral immune response to the viral spike protein and antibody effector functions during acute phase of infection and at 6-9 months follow-up. Antigen-specific B cells, CD4+ and CD8+ T cells were characterized, and T cells were interrogated for functionality at late convalescence. Anti-spike (S) antibody titers decreased over time, but effector functions mediated by S-specific antibodies remained stable. S- and nucleocapsid (N)-specific B cells could be detected in late convalescence in the activated memory B cell compartment and are mostly IgG+. CD4+ and CD8+ T cell immunity was maintained to S and membrane (M) protein. Asymptomatic infection resulted in decreased ADCC and frequency of SARS-CoV-2-specific CD4+ T cells at late convalescence. Whereas anti-S antibodies correlated with S-specific B cells, there was no correlation between T cell response and humoral immunity. Hence, all aspects of a protective immune response are maintained up to nine months after SARS-CoV-2 infection in the absence of re-infection. One sentence summary Functional immune memory to SARS-CoV-2, consisting of polyfunctional antibodies, memory B cells and memory T cells are maintained up to nine months in a South-East Asian cohort in the absence of re-infection.

≥10 days (Figure S1B ). Overall, 70% of the patients displayed mild or moderate symptoms, 115 and 30% remained asymptomatic (Table S1) . For all assays, samples were selected based on 116 availability and quality. 117

Asymptomatic and mild/moderate infection induces a persisting anti-spike antibody response. 118

The presence of S-binding antibodies was measured using the S-Flow assay, which sensitively 119 and quantitatively measures anti-S IgG, IgA, and IgM by flow cytometry (19, 37) (Figure 1A) . 120

The National Institute for Biological Standards and Control (NIBSC) references were utilized 121 to validate the assays and pre-pandemic samples obtained from nineteen individuals were 122 measured to set the cutoff for each assay (Figure S2 ). Anti-S IgM, IgG, and IgA titers decreased 123 significantly between acute phase and late convalescence (p=0.02, p<0.0001, p<0.0001, 124 respectively). (Figure 1B) . Within the total S-binding antibodies, the percentage of anti-S IgM 125

and IgA decreased whereas anti-S IgG increased over time (p=0.0003, Figure 1C ). The 126 detection of neutralizing antibodies was achieved by foci reduction neutralization test using a 127

Cambodian SARS-CoV-2 isolate. There was no difference in the titers of SARS-CoV-2 128 neutralizing antibodies between the acute and convalescent phase, even though titers tended to 129 decrease over time (Figure 1D) . Over time, the percentage of individuals positive for anti-S 130 7 together, these data show that despite decreases in antibody titers over time, the percentage of 137 individuals positive for anti-S IgG remains stable. 138

Besides neutralization, antibodies can mediate Fc-effector functions, such as complement 140 activation, killing of virus-infected cells and phagocytosis of viral particles (18). To further 141 define the humoral response in these individuals, we assessed antibody effector functions in 142 vitro. The NIBSC references were utilized to validate the assays and nineteen pre-pandemic 143 samples were measured to set the cutoff for each assay. Antibody-dependent cellular 144 phagocytosis (ADCP) assay measures the engulfment of neutravidin beads coated with SARS-145

CoV-2 derived S1 by THP-1 cells (Figure 2A, S4) . A decrease in ADCP can be observed 146 between the acute and late convalescent phase (p=0.005, Figure 2B , C). The percentage of 147 subjects with ADCP activity decreased from 73% to 55% over time. However, when calculating 148 the proportion of ADCP within the total anti-S antibodies, we observed a significant increase 149 of the proportion of ADCP over time (p=0.003, Figure 2D ). 150

Next, to evaluate the contribution of anti-S antibodies to complement dependent 151 cytotoxicity (CDC), we assessed cell death in Raji cells engineered to express S protein in the 152 presence of normal human serum as source of complement (Figure 2E, S5) (19) . No differences 153 in CDC activity was observed between the acute and late convalescent phase, where 60% and 154 56% of the subjects showed CDC activity, respectively (Figure 2F, G) . The proportion of CDC-155 mediating antibodies within the total anti-S antibody fraction significantly increased between 156 acute and late convalescence (p=0.0002, Figure 2H ).

(ADCC) activity was measured using S-expressing 293T cells as target cells with degranulation 160 measured by CD107a staining in primary NK cells as a readout for ADCC (Figure 2I, Figure 161 S6). ADCC activity did not change between the acute and late convalescent phase (Figure 2J, 162 K) . At both time points, 59% -66% of individuals showed anti-S mediated ADCC activity. 163

However, similar to ADCP and CDC, the proportion of ADCC-mediating antibodies within the 164 fraction of anti-S antibodies increased significantly over time (p<0.0001, Figure 2I ). Analyzing 165 only individuals with paired samples available, revealed similar results as the cohort as a whole 166 (Figure S3, . Overall, these data show that antibody effector functions mediated by S-167 specific antibodies remain stable over time and that the proportion of the functional antibody 168 response within the total anti-S antibodies increases over time. 169

spike and nucleocapsid protein 6-9 months after infection 172

Upon re-infection, memory B cells are rapidly activated to differentiate into antibody-producing 173 plasmablasts and/or re-initiate germinal centers in the case of secondary heterologous infection 174 with antigenically similar pathogens (38). Therefore, they may play an important role in long-175 term immunity to SARS-CoV-2 and their evolving variants. We assessed the phenotype and 176 frequency of antigen-specific memory B cells by staining with site-specific biotinylated 177 recombinant S1 and N protein (Figure 3A, S7A, B) . At late convalescence, 0.10% of the total 178 CD27 + B cells are S1-specific, whereas 0.66% are N-specific (p<0.0001, Figure 3B ). (Figure 179 3C, D). The proportion of CD27 + CD38 + S1-specific B cells (75%, IQR=30%) is significantly 180 increased compared to the proportion of CD27 + CD38 + N-specific B cells (39%, IQR=26%, 181

Mann-Whitney Test, p<0.0001) (Figure 3E ). Moreover, the proportion of S1-versus N-specific 9 B cells varies within each CD27 + B cell subset (p<0.0001, Figure 3F ). We next analyzed S1-183 and N-specific B cells within the unswitched (IgD -IgM + ) and switched (IgD -IgG + and IgD -IgA + ) 184 B cell compartments ( Figure S7A ). S1-specific B cells were mainly IgD -IgG + , whereas N-185 specific B cells were either IgD -IgM + or IgD -IgG + (Figure 3G, H) . The proportion of IgD -IgG + 186 S1-specific B cells (75%, IQR=24%) was significantly increased compared to the proportion 187 of IgD -IgG + N-specific B cells (37%, IQR=17%) (p<0.0001) ( Figure 3I ). Therefore, within each 188 switched B cell subset, the proportion of S1-versus N-specific B cells was different (p<0.0001) 189 (Figure 3J) . Taken together, SARS-CoV-2 infection induces a robust memory B cell response 190 targeting both S and N. 191

CD8 + T cells that are maintained up to 6-9 months after infection. 194 In addition to humoral immunity, the generation and maintenance of virus-specific cellular 195 immune responses is critical to help prevent reinfection. phenotypes of SARS-CoV-2-specific memory T cell responses are still under investigation (24, 197 39, 40) . SARS-CoV-2-specific CD4 + and CD8 + T cells were assessed in 33 individuals at late 198 convalescence by incubating PBMCs with peptide pools covering immunodominant sequences 199 of the viral S1, M and N protein ( Figure 4A ). Post incubation, activation induced marker (AIM) 200 assays identified CD4 + antigen-specific cells using OX40 + CD137 + combined with phenotypic 201 markers to measure different memory and T helper (Th) subsets . Percentages 202 of both S1-and M-specific CD4 + T cells were significantly increased compared to the 203 percentage of N-specific cells (p<0.0001, p=0.0002), Figure 4B ). Phenotypically, 42% of virus-204 specific T cells displayed an effector memory phenotype (CD45RA -CCR7 + ) and 87% of the 205 cells showed a Th1-skewed phenotype (CXCR3 + CCR6 -) (Figure 4C, D) . Comparing the 206 memory phenotype of S1-, M-and N-specific cells, we observed that a lower proportion of S1-207 specific cells displayed an effector memory phenotype (23%) compared to M-specific cells 208 (41%, p=0.0457) and N-specific cells (58%, p<0.0001) ( Figure S9A ). Moreover, 97% of M-209 specific cells showed a Th1-skewed phenotype compared to only 65% (p<0.0001) of the S1-210 specific cells and 71% (p=0.0130) of the N-specific cells ( Figure S9B ). In eight individuals, 211 sufficient cell numbers were available to assess functionality by cytokine production after 212 peptide stimulation using a multi-parameter ex vivo intracellular cytokine staining (ICS) assay 213 ( Figure S8E ). SARS-CoV-2-specific CD4 + T cells produced Interleukin (IL)-2 (36%) or IL-6 214 (28%) after peptide stimulation, and were polyfunctional (Figure 4 E, F) . Percentages of IL-2 + 215 and IL-17 + cells were significantly higher after S1 stimulation compared to M stimulation 216 (p=0.046, p=0.017) ( Figure S9C ). 217

Next, we assessed the frequency and phenotype of cytotoxic CD8 + T cells by AIM assay 218 using CD69 + CD137 + to identify antigen-specific CD8 + T cells. Frequency of total SARS-CoV-219 2-specific CD8 + cells is 0.44% ( Figure 5A ) with 61% of these SARS-CoV-2-specific CD8 + T 220 cells being terminally differentiated effector memory cells (TEMRA, CD45RA + CCR7 -) (Figure 221 5B, Figure S9D ). No differences were observed between S1-, M-and N-specific CD8 + T cells. 222 Similar to antigen-specific CD4 + T cells, SARS-CoV-2-specific CD8 + T cells produced either 223 IL-2 (56%) or IL-6 (16%) after peptide stimulation, and were polyfunctional (Figure 5 C, D) , 224 (Figure S9E ). Interestingly, 2/33 (6%) individuals displayed no CD4 + T cell reactivity, and 6/33 225 (19%) individuals lacked a CD8 + T cell response after stimulation. In summary, sustained and 226 functional CD4 + and CD8 + T cell responses are detected in the study participants, even after 227 experiencing only mild or asymptomatic SARS-CoV-2 infection. These data suggest that 228 SARS-CoV-2 can induce a long-lived cellular immune response, which could confer protection 229 after reinfection or could be reactivated with vaccination. 230

SARS-CoV-2-specific CD4 + T cells observed 6-9 months after infection. 232

In order to assess if symptomatic disease is associated to altered immune memory formation, 233 we compared the functional immune response between asymptomatic and symptomatic patients 234 with mild/moderate clinical presentation. Overall, no differences occurred in the humoral 235 parameters assessed in the acute phase of infection ( Figure 6A , S10). At late convalescence, 236 symptomatic disease is associated with increased ADCC activity compared to asymptomatic 237 individuals (p=0.0034) ( Figure 6A ). Moreover, percentages of N-specific CD27 + B cells, but 238 not S1-specific, were increased in asymptomatic individuals versus patients who were 239 symptomatic (p=0.051) ( Figure 6B ). Symptomatic disease was also significantly associated 240 with increased percentage of SARS-CoV-2-specific CD4 + T cells (p=0.0018) with a central 241 memory phenotype (p=0.0498) (Figure 6C, D) . These data suggest that the outcome of acute 242 infection has an imprint on the memory immune response with implications for response to 243 subsequent infection or vaccination. 244

In order to assess the relation between antibody titers, functional humoral immunity, and the 246 cellular T and B cell compartment we performed extensive correlation analysis (Figure 7 ). Age 247 correlated to anti-S antibody titers and S1-specific CD19 + IgD -IgG + and CD19 + CD27 + B cells. 248

In the acute phase of infection, anti-S IgG, IgM and IgA titers, functionality, measured by 249 seroneutralization, and effector functions correlated. Seroneutralization, anti-S IgA, and ADCC 250 correlated over time, albeit not very strong. Antibody effector functions 2-9 days post 251 laboratory confirmation negatively correlated with total antigen-specific and S1-specific CD4 + 252 T cells at late convalescence. 253

At late convalescence, anti-S IgG correlated with all three effector functions, but not 254 with neutralizing capacity. Within the B cell compartment, N-specific IgG + , IgA + and CD27 + 255 B cells correlated to one another, as did S1-specific IgG + , IgA + and CD27 + B cells. No 256 correlation was identified between S1-and N-specific B cells. Anti-S IgG titers, ADCP, and 257 CDC correlated with S1-specific IgG + and CD27 + B cells. The S1-specific CD4 + T cell 258 responses correlated with S1-specific CD8 + T cell responses, but did not correlate to antibody 259 titers nor to effector functions or to S1-specific B cells. Overall, different aspects of a functional 260 immune memory response do not fully correlate with one another and require separate 261 evaluation when considering long-term immunity to SARS-CoV-2. 262 263

In this study, we investigated a partially asymptomatic cohort of Cambodian individuals 265 in the acute and late convalescent phase for anti-S antibody titers, neutralization and effector 266 functions, as well as SARS-CoV-2-specific B and T cell responses. As Cambodia was relatively 267 COVID-19-free throughout 2020 (35), it is highly unlikely this cohort had additional exposure 268 events after inclusion in this study, that could have boosted their immunity to SARS-CoV-2. 269

One limitation is the uncertainty of the exact timing of exposure/infection, as infections were 270 identified by screening at entry into Cambodia rather than in a direct surveillance or community 271 cohort. 272

Studies assessing long-term immunity to SARS-CoV-2 in Asian populations are scarce 273 (16, (32) (33) (34) 41) . In addition, studies on cross-reactivity of the humoral and cellular compartment 274 13 with other hCoVs have mainly focused on European and US populations (42-45). Historically, 275 the population in East Asia seems to be more exposed to coronavirus-like viruses as only East 276

Asian population show genetic adaptation to coronaviruses (46). The main natural reservoir of 277 SARS-related coronaviruses is believed to be Horseshoe bats (genus Rhinolophus), which are 278 endemic to Southeast Asia and China (47-49). Whether possible cross-reactivity to other 279 coronavirus-like viruses or hCoVs may have influenced the adaptive immune response to 280 SARS-CoV-2 in Southeast Asian populations remained to be investigated. 281

As expected, anti-S IgM, IgG and IgA titers declined over time and anti-S IgG becomes 282 the major isotype at late convalescence (24, (50) (51) (52) . In this study, IgA titers were the most 283 affected over time. The formation of anti-S IgA is shown to be dependent on local lung 284 inflammation (53-55) hence titers decline the strongest in asymptomatic/mild patients. Titers 285 of neutralizing antibodies are reported to reach their maximum within the first month after 286 infection and then decay, but mostly remain detectable six months and even up to one year after 287 infection (10, 24) . A relatively low rate of individuals retained neutralizing antibodies at late 288 convalescence in this cohort (56%) as most longitudinal studies found 76-98% of individuals 289 remaining positive (19, 24) . This might be attributed to the absence of possible re-exposure 290 and/or the consequence of asymptomatic/mild infection (10, 26, 39, 51) . In contrast with other 291 papers, neutralizing titers did not correlate to anti-S IgG antibodies at late convalescence. This 292 might be due to varying relative contribution of anti-S IgG, IgM and IgA to SARS-CoV-2 293 neutralization at late convalescence, the genetic background of the participants or can be due to 294 the different technique to measure anti-S binding and neutralizing antibodies (56, 57). 295

Fc-mediated effector functions contribute to clearance of virus-infected cells but are 296 often critically overlooked. SARS-CoV-2 infection induces Fc-mediated effector functions 297 irrespective of disease outcome (19-21). Antibody effector functions develop rapidly after 298 infection and correlate with anti-S IgG and neutralizing titers in the acute phase and at late 299 convalescence (19, 20) . In this current study, between 55-66% of individuals showed antibody 300 effector function activity up to nine months after infection. Also, ADCC persisted in a higher 301 percentage of individuals compared to neutralization or other effector functions (22, 23). We 302 report here the maintenance of CDC over time suggesting that both ADCC and CDC can 303 contribute to protection from re-infection. ADCP levels decreased over time which could have 304 consequences for antigen presentation and macrophage activation upon re-infection (58). 305

Interestingly, the ratio of S-mediated effector functions over total anti-S IgG increases over 306 time. Together with reports showing the evolution of the BCR repertoire over time (26, 59, 60) , 307

these data indicate ongoing affinity maturation and evolution of the antibody response to a more 308 functional response. Therefore, measurement of only S-binding antibodies at late 309 convalescence does not reflect their function. 310 S-, RBD-and N-specific memory B cells are maintained more than six months post 311 symptom onset and their frequency increased over time (24, 61, 62) . In this cohort, S1-and N-312 specific memory B cells persisted up to 6-9 months post infection with some variability between 313 individuals. The percentage of S1-specific IgG B cells correlated with S-specific IgG 314 antibodies, and S1-specific B cells displayed an activated phenotype. This suggests that these 315 B cells could be recruited after secondary exposure with SARS-CoV-2 and might confer some 316 level of protection against infection with new variants via additional diversification trough 317 germinal center responses (38). 318

Anti-SARS-CoV-2 T cell immunity was assessed by AIM, which is a sensitive assay 319 that provides a broader picture of the overall antigen-specific T cell response, compared to 320 cytokine-detection based assays (6, 63). Persistence of functional memory T cells after SARS-321

CoV-2 infection has been reported, also after asymptomatic infection (24, 64) . Similar to other 322 reports, virus-specific memory CD4 + T cells were skewed to a Th1 or Th1/Th17 profile and 323 displayed mainly an effector memory (CD45RA -CCR7 -) phenotype (27, 64, 65) . Virus-specific 324 CD8 + T cells consisted mostly of cells with a TEMRA phenotype, a compartment of cytotoxic 325 CD8 + T with limited proliferative potential (66). Polyfunctional virus-specific CD4 + and CD8 + 326 T cells could be detected, mainly secreting IL-2 (16, 39), albeit we could only include few 327 individuals in this analysis. Similar to other long-term cohorts, virus-specific CD4 + and CD8 + 328 cells can be detected in up to 90% -70% of the individuals, respectively (4). 329

Differences in frequency and phenotype of N-and S-specific B and T cells has been 330 reported before (24, 27, 39, 67) . This might be due to the difference in antigen availability, 331 persistence, and immunological context. Together with other envelope proteins, S proteins 332 cover the surface of the virus and bind to the host cell, while the N protein underlies viral 333 packaging and hence is less accessible (68). The N protein is more conserved among 334 coronaviruses (68), whereas S protein and especially the RBD-bearing S1 subunit are more 335 prone for acquiring mutations (69, 70). Consequently, anti-N IgG rather than anti-S1 IgG can 336 be found in individuals not exposed to 71, 72) . This might explain the 337 observed higher frequency of N-specific B cells in our study. 338

Correlations between CD4 + T cells and humoral responses can be observed in some 339 long-term cohorts (27, 29, 73, 74) but not all (24). In this study, there was no correlation 340 between the S-specific cellular and humoral immune compartment at late convalescence. 341 Therefore, neither anti-S IgG nor neutralizing antibodies are a good proxy to determine the 342 cellular response to SARS-CoV-2. Moreover, correlations between anti-S antibody titers and 343

Fc-related functions at late convalescence are weak and subtle differences might lead to a 344 different disease outcome upon re-exposure. Hence, serological testing alone might not be 345 sufficient to understand the full spectrum of long-term immunity generated after SARS-CoV-2 346 infection. 347

The development, characteristics and functionality of the totality of long-term immunity 348 in asymptomatic infected individuals remains to be further characterized. We observed an 349 increase of ADCC at late convalescence in patients who had mild/moderate disease compared 350 to asymptomatic individuals. This observation is in line with studies showing increased anti-S 351 IgG afucosylation in severe patients compared to mild and asymptomatic cases (75, 76). Indeed, 352 afucosylated monoclonal antibodies can cause elevated ADCC though increased IgG-FcγRIIIa 353 affinity (77, 78). More severe COVID-19 induced a stronger SARS-CoV-2-specific CD4 + T 354 cell response (27-29). We confirm and extend these data as we observed lower levels of virus-355 specific CD4 + T cells in asymptomatic individuals compared to mild/moderate cases. These 356 data suggest that different disease outcome after infection results in altered long-term immunity, 357 which could shape the response to subsequent infection or vaccination. 358

Taken together, our work shows additional evidence of long-term and persistent 359 immunity after asymptomatic and mild SARS-CoV-2 infection. Furthermore, this cohort 360 describes the immune response in individuals of Asian origin and in the absence of re-exposure 361 to SARS-CoV-2. We show the persistence of humoral immunity, antibody effector functions, 362 and virus-specific memory T and B cells 6-9 months after infection, which do not correlate to 363 each other. These data enhance our understanding of long-term functional immunity. Cambodge before the onset of the pandemic were included to validate the antigen-specific B 374 and T cell staining. Acute SARS-CoV-2 infected patients were identified via screening of 375 imported cases in Cambodia between 6 th March to 12 th August 2020. All laboratory confirmed 376 cases are quarantined and monitored for symptoms. Moreover, 1-15 follow-up 377 nasopharyngeal/oropharyngeal swab samplings for SARS-CoV-2 detection were conducted to 378 assess viremia. Patients were only discharged after two consecutive negative RT-PCR tests 379 within 48h. Symptomatic patients displayed mild/moderate symptoms such as running nose, 380

cough, fever and difficult to breath. In total, we included 64 individuals for follow up. In 33 381 individuals, 2-9 days after laboratory confirmation, a blood sample was obtained. A second 382 blood sample was obtained 6-9 months later from all 64 study participants. Participant 383 characteristics and clinical signs are summarized in Table S1 

Molecular detection of SARS-CoV-2 in combined nasopharyngeal/oropharyngeal swabs was 391 performed as previously described (36). Briefly, RNA was extracted with the QIAamp Viral 392 RNA Mini Kit (Qiagen) and real-time RT-PCR assays for SARS-CoV-2 RNA detection were 393 performed in using primers/probes from Charité Virologie (Berlin, Germany (79)) to detect 394 both E and RdRp genes. 395

The detection of neutralizing antibodies was achieved by foci reduction neutralization test 397 (FRNT) similar as described before (80) 

The S-Flow assay was performed as previously described (37) 

Biotinylated SARS-CoV-2 S1 protein and biotinylated SARS-CoV-2 N protein were purchased 478 from GenScript. The biotinylated proteins were combined with different streptavidin (SA) 479 fluorophore conjugates, BUV496 (BD Biosciences) and PE (Biolegend), respectively, at 1:1 480 molar ratio. Briefly, each SA was added gradually (3 times, every 20 minutes) to 20 µl of each 481 biotinylated protein (1 µM) on ice. The reaction was quenched with D-biotin (GeneCopeia) at 482 50:1 molar ratio to SA for a total probe volume of 30 µl for 30 minutes on ice. Probes were 483 then used immediately for staining. Each staining used 5 µl of probe. Shortly, patient PBMCs 484 was washed with 1xPBS and stained with Zombie Aqua viability dye (BioLegend) for 10 485 minutes on ice. The cells were stained with the probes. Then the cells were washed and stained 486 with anti-IgG antibody, for 30 minutes on ice. After that, the cells were washed and stained 487 with master mix containing of anti-CD3, anti-CD19, anti-CD27, anti-CD38, anti-IgD, anti-IgM 488 and anti-IgA antibodies for 30 minutes on ice Antibodies are listed in Table S2 . After staining, 489 the cells were washed and resuspended in 1xPBS with 2% FBS. The samples were analyzed 490 using FACS Aria, BD Biosciences. The flow cytometry gating strategy to classify memory B 491 cell subsets and switched B cells is shown in Figure S7 . Overall, 40 samples were of sufficient 492 quality and were included in the analysis. 493

Antigen-specific CD4 + and CD8 + T cells, as well as memory T cells and T helper subsets were 495 assessed by Activation-Induced Marker (AIM) assay (6, 24). Cells were cultured at 37°C, 5% 496 CO2, in the presence of SARS-CoV-2-specific S1, M and N protein pools [1 µg/mL] 497 (PepTivator® SARS-CoV-2 regents; Miltenyi Biotec) in 96-well U-bottom plates at 0,5-1x10 6 498 PBMCs per well. After 24 hours, cells were washed in 1xPBS supplemented with 0.5% bovine 499 serum albumin (BSA) and 2 mM EDTA (FACS buffer) and stained with Zombie Aqua Fixable 500 Viability kit (Biolegend) and incubated for 20 min at 4°C followed by surface staining for 30 501 min at 4°C. Stained cells were washed and resuspended in FACS buffer and analyzed using a 502

FACSAria Fusion (BD Biosciences). Antibodies are listed in Table S2 . Negative controls 503 without peptide stimulation were included for each donor. Antigen-specific CD4 + and CD8 + T 504 cells were measured subtracting the background (unstimulated control) from the peptide-505 stimulated sample. Negative results were set to zero. Data were analyzed with FlowJo software 506 version 10.7.1 (FlowJo LLC). Overall, 33 samples were of sufficient quality and were included 507 in the analysis. 508 binding was calculated as 100 x (% binding on S-expressing 293T cells -% binding on 293T 10 control cells)/(100-% of binding to 293T control cells). Graph shows data from triplicate testing 11 of the COVID-19 reference plasma panel (NIBSC 20/120, 20/124, 20/124, 20/126, 20/128, 12 20/130) obtained from the NIBSC. 13 neutravidin beads coated with biotinylated S1 protein. Representative ADCP assay using the 37 COVID-19 reference plasma panel (NIBSC 20/120, 20/124, 20/124, 20/126, 20/128, 20/130) Representative gating strategy. (B) CDC assay was performed by using pike-expressing Raji 45 cells as target cells, serum (pooled from 3 healthy donors) as complement source and heat-46 inactivated plasma from SARS-CoV-2 patients or from reference panel as antibody source. 47 CDC activity was measured as the percentage of C3 + Zombie + pike-expressing Raji cells after 48 incubation with plasma and complement. Representative CDC assay using the COVID-19 49 reference plasma panel (NIBSC 20/120, 20/124, 20/124, 20/126, 20/128, 20/130) ADCC activity of NK cells induced by incubation with COVID-19 reference plasma panel 58 (NIBSC 20/120, 20/124, 20/124, 20/126, 20/128, 20/130) 

A Novel Coronavirus from 538 Patients with Pneumonia in China

Epidemiological and clinical 540 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 541 descriptive study

Clinical Characteristics of 543 Coronavirus Disease 2019 in China

Adaptive immunity to SARS-CoV-2 and COVID-19

550 Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with

CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected 554 individuals

Structural and Functional 556 Basis of SARS-CoV-2 Entry by Using Human ACE2

Structural basis for the recognition of 558 SARS-CoV-2 by full-length human ACE2

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and 561 critical for survival

A longitudinal study 566 of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies 567 and COVID-19 severity

DNA 569 vaccine protection against SARS-CoV-2 in rhesus macaques

Antibody potency, effector function, and combinations in protection and therapy for SARS-573

CoV-2 infection in vivo

One-year 575 durability of anti-spike IgG to SARS-CoV-2: preliminary data from the AntiCROWN 576 prospective observational study One year durability of COVID-19 anti-spike IgG

Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after 580 SARS-CoV-2 Infection

582 Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. 583 Nature. 2021

Fcγ Receptor Function and the Design of Vaccination 585 Strategies

Asymptomatic 587 and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

Markers of 590 Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma

Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

595 Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent 596 individuals up to eight months post-symptom onset

Fc-dependent antibody functions after mild to moderate COVID-19

Immunological 601 memory to SARS-CoV-2 assessed for up to 8 months after infection

COVID-19 immune signatures reveal stable antiviral T cell function despite declining 605 humoral responses

607 Evolution of antibody immunity to SARS-CoV-2

CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Long-615 term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering 616 from COVID-19 with and without post-acute symptoms

CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. 619

Longitudinal 623 assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical 624 severity of COVID-19. The Journal of Infectious Diseases. 2021. 625 33

Immune memory in 629 convalescent patients with asymptomatic or mild COVID-19

Assessment of 633 inactivation procedures for SARS-CoV-2

A 635 comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human 636 serum samples from different populations

Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell 639 Reactivation by Boosting

CoV-2-Specific Immune Memory Persists after Mild COVID-19

Broad and strong memory 644 CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following 645 COVID-19

Dynamics of 647 SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Shared B 650 cell memory to coronaviruses and other pathogens varies in human age groups and tissues

T cell assays 653 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral 654 responses

Clonal 656 analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-657 2. Science. 2021. 658 45

The major genetic risk factor for severe COVID-19 is inherited 662 from Neanderthals

A pneumonia 664 outbreak associated with a new coronavirus of probable bat origin

Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in 668 Southeast Asia

A novel 670 SARS-CoV-2 related coronavirus in bats from Cambodia

Estimated half-life of SARS-672

CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in 673 healthcare workers

An 678 ancient viral epidemic involving host coronavirus interacting genes more than 20,000 years 679 ago in East Asia

Persistence 681 of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-682 8 months after the infection

Profiling Early Humoral 684 Response to Diagnose Novel Coronavirus Disease (COVID-19)

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe 688 COVID-19

IgA dominates the 690 early neutralizing antibody response to SARS-CoV-2

Major role of IgM in 692 the neutralizing activity of convalescent plasma against SARS-CoV-2

Antibody-Dependent Cellular Phagocytosis in Antiviral 695 Immune Responses

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Profiling B 700 cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-701 neutralizing viral targets

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from 707 COVID-19 Patients

Comparative 709 analysis of activation induced marker (AIM) assays for sensitive identification of antigen-710 specific CD4 T cells

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

715 Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection 716 with persisting antibody responses and memory B and T cells

Molecular 719 signatures distinguish human central memory from effector memory CD8 T cell subsets

Rapid 722 generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in 723 COVID-19 and convalescence

The 725 SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. 726 Nature Communications

Characterizations 728 of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infection, 729 Genetics and Evolution

SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the 732 COVID-19 Virus

Preexisting and 734 de novo humoral immunity to SARS-CoV-2 in humans

Cross-reactive 736 serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic 737 coronavirus infection

Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4(+) T cell 743 help

Proinflammatory IgG Fc structures in patients with severe COVID-19

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 749 severity

Lack of fucose on 751 human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and 752 antibody-dependent cellular toxicity

The "less-is-more" in therapeutic antibodies

Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity

Detection 757 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Europeen sur les maladies transmissibles = European communicable disease bulletin

Broad and long-lasting 761 immune protection against various Chikungunya genotypes demonstrated by participants in a 762 cross-sectional study in a Cambodian rural community

This publication has been supported by WHO Solidarity II, global serologic study for COVID-766 19, with funding from the German Federal Ministry of Health (BMG) COVID-19 Research and 767 development to WHO

We would like to thank Borita Heng for her technical assistance

The study was funded by the Howard Hughes Medical Institute (HHMI)-Wellcome Trust 770

H.A. is supported by the German Centre for International Migration 772 and Development (CIM). The graphical abstract was created with BioRender

Cohort management and patient selection: SL, SL

Representative gating strategy used to define antigen-specific B cells

A) B cells were defined from the gates of morphology of lymphocytes, singlets

B). Total B cells (CD19 + ) were further gated for B cell subsets including resting 64

S1-specific B cells and N-specific B cells were determined. (C) Total B cells 66 (CD19 + ) were further gated for B cell classes including non-class-switched mature cells

IgM + ) and class-switched IgM -IgD -IgA + and IgM -IgD -IgG + cells. The S1-specific B cells and

N-specific B cells were determined. (D) Representative image comparing S1-and N-specific B 69 cells in healthy controls and SARS-CoV-2-infected patients 6-9 months post infection

The authors declare no competing interests 782